The Current Management Options for Patients With Heavy Treatment Ovarian Cancer

The VAC is a vaccinia virus, which has been genetically altered to only replicate in a thymidine-enriched environment. Cancer cells being rapidly dividing or rich in thymidine so they selectively infect cancer cells and essentially kill the cell. In the process of this, the cancer cells are releasing oncoproteins, which be foreign and recognized by the T cells,. This can affect an immune effect on the cancer. The overall response rates range anywhere from 10% to 30%. Average time-month therapy is three to four months, and survival is typically less than a year after treatment.